Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystonia

Drugs mentioned

• VIM0423

Snippet

Sponsor: Vima Therapeutics | Conditions: Dystonia | Phase 2 | Status: RECRUITING